[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: MERS treatment in development in China Want... A representative of the Institute of Microbiology under the Chinese Academy of Sciences (CAS) recently stated that they are developing antibodies and drugs to treat Middle East Respiratory Syndrome (MERS). They are still in the experimental stages, although they will soon proceed to human trials, according to our Chinese-language sister paper Want Daily. Mainland China recently confirmed an imported case of MERS from South Korea, while South Korea has seen 35 confirmed cases, which have led to the death of two people. MERS is an infectious respiratory illness caused by a new type of corona-virus. The first documented case was discovered in Saudi Arabia in 2012; in May 2013, the World Health Organization named it MERS. Experimental Treatment In a June 3 report from China Radio International, Wu Ying, an assistant researcher at the Institute of Microbiology under the CAS, said that the Key Laboratory of Pathogenic Microbiology and Immunology there has begun to research MERS antibodies and has already got an understanding of the mechanism by which the virus invades host cells. Wu stated that the research team has successfully identified the mechanism by which the virus spreads to humans, and that this can be used in the development of an inhibiting drug. These results were published in US journal Nature. The antibodies developed have already been tested on mice and proven successful; however, human trials are still pending, until further investigation has been carried out. HR2P Polypeptide China Science Daily cited comments from Jiang Shibo, an academic at the Key Laboratory of Medical Molecular Virology, Ministry of Education and Health at Fudan University, saying that from 2013 to 2014, he and his team had designed and observed a MERS-resistant polypeptide-HR2P and discovered that it was effective at inhibiting infection of cells by MERS-CoV. Jiang and his research team are now working on improving the HR2P polypeptide to develop a new one-HR2P-M2, which will be a soluble anti-viral which is more stable and active. Jiang said that based on current results, the polypeptide could be taken as a nasal spray by at-risk groups, including the close relatives of people who have been infected by the virus and the medical staff treating them, as an emergency preventative measure. Jiang added that those infected with the virus could also take the polypeptide to reduce the chance of infecting others. Poster Comment: China surpassed the West in consumer goods manufacture. Encouraging to see them making progress in biological research. Better than US spending money on development of war machines to fight enemies of its Shylockian manipulators who fund Israel-supporting members of Congress at election time. develop a new one-HR2P-M2, which will be a soluble anti-viral which is more stable and active but has no serious side effects. Post Comment Private Reply Ignore Thread Top • Page Up • Full Thread • Page Down • Bottom/Latest Begin Trace Mode for Comment # 1.
#1. To: Tatarewicz (#0)
Big amen!
There are no replies to Comment # 1. End Trace Mode for Comment # 1.
Top • Page Up • Full Thread • Page Down • Bottom/Latest |
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||